Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration?

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Hirsch, E C ^a   Hunot, S ^a   Damier, P ^a   Faucheux, B ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; NITRIC OXIDE;

CONFERENCE PAPER; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GLIA CELL; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SCAVENGING SYSTEM; SUBSTANTIA NIGRA;

EID: 0031715925     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440717     Document Type: Conference Paper

References (61)

1. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
2. Tretiakoff C. Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie de troubles du tonus musculaire et de la maladie de Parkinson. Thèse de Médecine, Paris, 1919
3. Ehringer H, Hornykiewicz O. Vertailung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 1960;38:1236-1239
4. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease? Neurology 1980;30:1326-1330
5. Hirsch EC, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348
6. Fearnley JM, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2302
7. Damier P, Hirsch EC, Agid Y, Graybiel AM. Temporosparial progression of the loss on dopaminergic neurons in the substantia nigra in Parkinson's disease [abstract]. Mov Disord 1997; 12(Suppl 1):274
8. Olszewski J, Baxter D. Cytoarchitecture of the human brainstem. Philadelphia: JB Lippincott, 1954
9. Hirsch EC. Parkinsonism and cell vulnerability. In: Proceedings of the 8th International Round Table on Neurodegenerative diseases (Rhône Poulenc Rorer Foundation), Annecy, 13-14 May, 1993. Neurodegenerative diseases. New York: Academic Press, 1994:155-167
10. Damier P, Hirsch EC, Zhang P, et al. Glutathione peroxidase glial cells and Parkinson's disease. Neuroscience 1993;52:1-6
11. Damier P, Agid Y, Graybiel AM, Hirsch EC. Role of astroglial environment in selectivity of dopaminergic lesion in Parkinson's disease [abstract]. Soc Neurosci Abstr 1996;22:219
12. Lin LFH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132
13. Beck K, Knüsel B, Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des (1-3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 1993;52:855-866
14. +: specificity and impact of culture conditions, non-dopaminergic neurons, and astroglial cells. J Neurosci Res 1993;34:382-393
15. Otto D, Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 1990;10:1912-1921
16. Mayer E, Dunnett SB, Pellitteri R, Fawcett JW. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons. I Effects in vitro. Neuroscience 1993;56:379-388
17. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979;103:359-362
18. Damier P, Kastner A, Agid Y, Hirsch EC. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 1996;46:1262-1269
19. Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 1992;263:1-16
20. Dinarello C. Interleukin-1 and interleukin-1 antagonist. Blood 1991;77:1627-1652
21. Hétier E, Ayala J, Denefle P, et al. Brain macrophages synthesize IL-1 and IL-1 mRNAs in vitro. J Neurosci Res 1988;21: 391-397
22. Van Dam A, Brouns M, Louisse S, Berkenbosch F. Appearance of IL-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness? Brain Res 1992;588:291-296
23. Sébire G, Emilie D, Wallon C, et al. In vitro production of IL-6, IL-1β and tumor necrosis factor-α by human embryonic microglial and neural cells. J Immunol 1993;150:1517-1523
24. Guilian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 1985;228:497-499
25. Lachman LB, Brown DC, Dinarello CA. Growth promoting effect of recombinant IL-1 and TNF for human astrocyte cell line. J Immunol 1987;138:2913-2916
26. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits neuronal damage induced by cerebral ischaemia or NMDA-receptor activation in the rat. Brain Res Bull 1992;585: 135-160
27. Beasley D, Schwartz JH, Brenner BM. Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991;87:602-608
28. Logan A. CNS growth factors. Br J Hosp Med 1990;43:428-437
29. Berkenbosch F, Robakis N, Blum M. Interleukin-1 in the central nervous system: a role in the acute phase response and in brain injury, brain development, and the pathogenesis of Alzheimer's disease. In: Frederickson RCA, McGaugh JL, Felten DL, eds. Peripheral signaling of the brain. Toronto: Hogrefe & Huber, 1991:131-145
30. Giulian D, Woodward J, Young D, Krebs JF, Lachman LB. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1989;8:2485-2490
31. Hunot S, Betard C, Faucheux B, Agid Y, Hirsch EC. Immunohistochemical analysis of interferon-γ and interleukin-1β in the substantia nigra of Parkinsonian patients [abstract]. Mov Disord 1997;12(Suppl 1):20
32. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Ann Neurol 1994;180:147-150
33. Hirsch EC. Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur Neurol 1993;33:52-59
34. Hunot S, Boissière F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-363
35. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54:823-827
36. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992;149:2736-2741
37. Dawson VL, Brahmbhatt HP, Mong JA, Dawson TM. Expression of inducible nitric oxide synthase cause delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 1994;33:1425-1430
38. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991;88:6368-6371
39. Demerlé-Palladry C, Lonchamp MO, Chabrier PE, Braquet P. Nitric oxide synthase induction in glial cells: effect on neuronal survival. Life Sci 1993;52:1883-1890
40. Wink DA, Hanbauer I, Krishna MC, et al. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 1993;90:9813-9817
41. Hirsch EC, Faucheux BA. Iron metabolism and Parkinson's disease. Mov Disord 1998;13(Suppl 1):39-45
42. Van der Meide PH, Dubbeld M, Viverberg K, Kos T, Schellekens H. The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. J Gen Virol 1986;67:1059-1074
43. Dijkema R, Van Der Meide PH, Pouwels PH, et al. Cloning and expression of the chromosomal immune interferon gene of the tat. Eur Mol Biol Org 1985;4:761-767
44. Ijzermans JNM, Marquer RL. Interferon-gamma: a review. Immunobiology 1989;179:456-473
45. Merrill JE, Chen IS. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J 1991;5: 2391-2397
46. Morganti-Kossmann MC, Kossmann T, Wahl SM. Cytokine mediated neuropathology. Trends Pharmacol Sci 1992;13:286-291
47. Frei K, Nadal D, Fontana A. Intracerebral synthesis of tumor necrosis factor α and interleukin-6 in infectious meningitis. Ann NY Acad Sci 1990;594:326-335
48. Cogswell JP, Zelesnik-Le N, Ting JPY. Transcriptional regulation of the HLA-DRA gene. Crit Rev Immunol 1991;11:87-112
49. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291
50. Lee S, Liu W, Dickson D, Brosnan C, Berman J. Cytokine production by human foetal microglial and astrocytes. Differential induction by lipopolysaccharides and IL-1β. J Immunol 1993;150:2659-2667
51. Lieberman A, Pitha P, Shin H, Shin M. Production of TNF and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 1989; 86:6348-6352
52. Chung I, Benveniste E. TNFα production by astrocytes: induction by lipopolysaccharide, IFN and IL-1β. J Immunol 1989; 144:2999-3007
53. Sawada M, Kondo N, Suzumura A, Marunouchi T . Production of TNFα by microglia and astrocytes in culture. Brain Res 1989;491:394-397
54. Hétier E, Ayala J, Bousseau A, Denefle P, Prochiantz A. Amoeboid microglial cells and not astrocytes synthesize TNFα in Swiss mouse brain cell cultures. Eur J Neurosci 1990;2:762-768
55. Boka G, Anglade P, Wallach D, et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994;172:151-154
56. Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165:208-210
57. Tartaglia L, Weber R, Figari I, et al. The two different receptors for TNF mediate distinct cellular responses. Proc Natl Acad Sci USA 1991;88:9292-9296
58. Tartaglia L, Rothe M, Hu YK, Goeddel D. Tumor necrosis facror's cytotoxic activity is signalled by the p55 TNF receptor. Cell 1993;73:213-216
59. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997;94:7531-7536
60. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system I: expression and recognition. Trends Neurosci 1995;18:83-88
61. Henderson B, Blake S. Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci 1992;13:145-152